Recent progress in tight junction modulation for improving bioavailability

Abstract

Introduction: Currently, there are many novel drugs that belong to class III or IV of the Biopharmaceutics Classification System, showing low bioavailability. Tight junction (TJ) modulation offers an approach to increase bioavailability of pharmaceutical compounds. Furthermore, some diseases are accompanied by disturbed barrier function or TJ dysregulation and thus represent a second application for TJ modulators.

Areas covered: This review contains a summary of three different TJ modulators: AT1002, PN159 and labradimil. Within this summary, the authors provide a description of their effects on TJs, their adverse effects and their success in clinical trials. Furthermore, the authors present the current understanding of TJ regulation and highlight opportunities to develop new TJ modulators; they also review the problems that might occur.

Expert opinion: The development of new mechanism-based (MB) TJ modulators is a very promising field of research. MB approaches are expected to have the best future prospects. Further elucidation of signaling pathways and TJ regulation will be necessary for advancing MB TJ modulator research.

Keywords::

• AT1002
• Cereport®
• labradimil
• modulation
• myosin light chain
• PN159
• regulation
• RMP-7
• signaling
• tight junction

View correction statement:

Erratum

Acknowledgment

D Saaber and S Wollenhaupt contributed equally to this review.

Notes

This box summarizes key points contained in the article.